These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 36156004)

  • 1. [The Development of Combinatorial Cancer Immunotherapy with Anti-PD-1 Therapy and Radiotherapy for Patients with Esophageal Squamous Cell Carcinoma].
    Mimura K; Kono K
    Gan To Kagaku Ryoho; 2022 Sep; 49(9):914-916. PubMed ID: 36156004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PD-L1 expression and its clinicopathological correlation in advanced esophageal squamous cell carcinoma in a Chinese population.
    Rong L; Liu Y; Hui Z; Zhao Z; Zhang Y; Wang B; Yuan Y; Li W; Guo L; Ying J; Song Y; Wang L; Zhou Z; Xue L; Lu N
    Diagn Pathol; 2019 Jan; 14(1):6. PubMed ID: 30684971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy for esophageal squamous cell carcinoma: a review.
    Mimura K; Yamada L; Ujiie D; Hayase S; Tada T; Hanayama H; Thar Min AK; Shibata M; Momma T; Saze Z; Ohki S; Kono K
    Fukushima J Med Sci; 2018 Aug; 64(2):46-53. PubMed ID: 30058598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advancements in immunotherapy for advanced esophageal squamous cell carcinoma: a comprehensive review of current strategies and future directions.
    Zhang Y; Li Z; Huang Y; Xu Y; Zou B
    Expert Rev Clin Immunol; 2024 Aug; 20(8):971-984. PubMed ID: 38884604
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Programmed cell death-ligand 1 expression predicts poor treatment response and prognostic value in esophageal squamous cell carcinoma patients without esophagectomy.
    Zhang F; Zhu X; Zhang Q; Zhou P; Hao L
    Aging (Albany NY); 2021 Jul; 13(14):18827-18838. PubMed ID: 34297698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RATIONALE 311: tislelizumab plus concurrent chemoradiotherapy for localized esophageal squamous cell carcinoma.
    Yu R; Wang W; Li T; Li J; Zhao K; Wang W; Liang L; Wu H; Ai T; Huang W; Li L; Yu W; Wei C; Wang Y; Shen W; Xiao Z
    Future Oncol; 2021 Nov; 17(31):4081-4089. PubMed ID: 34269067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic significance of tumor-infiltrating immune cells and PD-L1 expression in esophageal squamous cell carcinoma.
    Jiang Y; Lo AWI; Wong A; Chen W; Wang Y; Lin L; Xu J
    Oncotarget; 2017 May; 8(18):30175-30189. PubMed ID: 28404915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GITR agonistic stimulation enhances the anti-tumor immune response in a mouse model of ESCC.
    Wiles KN; Tsikretsis LE; Alioto CM; Hermida de Viveiros PA; Villaflor VM; Tétreault MP
    Carcinogenesis; 2022 Oct; 43(9):908-918. PubMed ID: 35880612
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased intraepithelial CD3+ T-lymphocytes and high PD-L1 expression on tumor cells are associated with a favorable prognosis in esophageal squamous cell carcinoma and allow prognostic immunogenic subgrouping.
    Jesinghaus M; Steiger K; Slotta-Huspenina J; Drecoll E; Pfarr N; Meyer P; Konukiewitz B; Bettstetter M; Wieczorek K; Ott K; Feith M; Langer R; Weichert W; Specht K; Boxberg M
    Oncotarget; 2017 Jul; 8(29):46756-46768. PubMed ID: 28657901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Perioperative immunotherapy for esophageal squamous cell carcinoma.
    Wei DD; Fang JM; Wang HZ; Chen J; Kong S; Jiang YY; Jiang Y
    Front Immunol; 2024; 15():1330785. PubMed ID: 38440724
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunological Responses Associated With Neoadjuvant Therapy in the Tumor Microenvironment of Esophageal Squamous Cell Carcinoma.
    Takehara Y; Tamaki T; Mimura K; Saito K; Neupane P; Tada T; Watanabe Y; Hayase S; Saze Z; Yoshimoto Y; Sato H; Kono K; Suzuki Y
    Anticancer Res; 2023 Oct; 43(10):4691-4700. PubMed ID: 37772585
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A tumor immune microenvironment-related integrated signature can predict the pathological response and prognosis of esophageal squamous cell carcinoma following neoadjuvant chemoradiotherapy: A multicenter study in China.
    Wu P; Zhang Z; Yuan Y; Zhang C; Zhang G; Xue L; Yang H; Wang L; Zheng X; Zhang Y; Yuan Y; Lei R; Yang Z; Zheng B; Xue Q; Sun N; He J
    Int J Surg; 2022 Nov; 107():106960. PubMed ID: 36257585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alleviation of neoadjuvant immunochemotherapy for esophageal squamous cell carcinoma and its relationship with expression and changes of PD-L1.
    Zhou YH; Li JY; Yan JX; Guo P; He WW; Liu Y
    Neoplasma; 2022 Jul; 69(4):785-793. PubMed ID: 35400168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. From pixels to patient care: deep learning-enabled pathomics signature offers precise outcome predictions for immunotherapy in esophageal squamous cell cancer.
    Li B; Qin W; Yang L; Li H; Jiang C; Yao Y; Cheng S; Zou B; Fan B; Dong T; Wang L
    J Transl Med; 2024 Feb; 22(1):195. PubMed ID: 38388379
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of PD-L1 expression on immune cells or tumor cells for locally advanced esophageal squamous cell carcinoma in patients treated with neoadjuvant chemoradiotherapy.
    Huang TC; Liang CW; Li YI; Guo JC; Lin CC; Chen YJ; Cheng AL; Hsu CH
    J Cancer Res Clin Oncol; 2022 Jul; 148(7):1803-1811. PubMed ID: 34432128
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comprehensive immunohistochemical analysis of tumor microenvironment immune status in esophageal squamous cell carcinoma.
    Hatogai K; Kitano S; Fujii S; Kojima T; Daiko H; Nomura S; Yoshino T; Ohtsu A; Takiguchi Y; Doi T; Ochiai A
    Oncotarget; 2016 Jul; 7(30):47252-47264. PubMed ID: 27322149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epigenetic modulation combined with PD-1/PD-L1 blockade enhances immunotherapy based on MAGE-A11 antigen-specific CD8+T cells against esophageal carcinoma.
    Wu Y; Sang M; Liu F; Zhang J; Li W; Li Z; Gu L; Zheng Y; Li J; Shan B
    Carcinogenesis; 2020 Jul; 41(7):894-903. PubMed ID: 32529260
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and Feasibility of Radiotherapy Plus Camrelizumab for Locally Advanced Esophageal Squamous Cell Carcinoma.
    Zhang W; Yan C; Gao X; Li X; Cao F; Zhao G; Zhao J; Er P; Zhang T; Chen X; Wang Y; Jiang Y; Wang Q; Zhang B; Qian D; Wang J; Zhou D; Ren X; Yu Z; Zhao L; Yuan Z; Wang P; Pang Q
    Oncologist; 2021 Jul; 26(7):e1110-e1124. PubMed ID: 33893689
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clonal Expansion of Tumor-Infiltrating T Cells and Analysis of the Tumor Microenvironment within Esophageal Squamous Cell Carcinoma Relapsed after Definitive Chemoradiation Therapy.
    Mori T; Kumagai K; Nasu K; Yoshizawa T; Kuwano K; Hamada Y; Kanazawa H; Suzuki R
    Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33499345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comprehensive Analysis of PD-L1 Expression, Immune Infiltrates, and m6A RNA Methylation Regulators in Esophageal Squamous Cell Carcinoma.
    Guo W; Tan F; Huai Q; Wang Z; Shao F; Zhang G; Yang Z; Li R; Xue Q; Gao S; He J
    Front Immunol; 2021; 12():669750. PubMed ID: 34054840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.